EMA Recommends Extension of Indications for Acalabrutinib to Include the Treatment for Patients with MCL By Ogkologos - April 3, 2025 819 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns the treatment of patients with relapsed or refractory mantle cell lymphoma Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Lurbinectedin Zongertinib Shows Durable Antitumour Activity in First-Line Treatment for Patients with Previously Untreated HER2-mutated Advanced NSCLC Patient Guide on Immunotherapy Side Effects and Their Management Now Available Also in the Ukrainian MOST POPULAR Niraparib Plus Abiraterone Acetate and Prednisone Improves rPFS and Other Clinically... August 8, 2023 Breathing for Stress Reduction March 10, 2021 Pregnancy is Safe After Early Breast Cancer in Young Women with... July 17, 2020 Adjuvant Everolimus Does Not Improve Recurrence-Free Survival Among Patients with Renal... August 9, 2023 Load more HOT NEWS Breast Cancer Development Spurred on by Prolactin Hormone, Studies Show How to Find the Right Hospice Care Program for You or... Mom Warns Others After Little Girl’s Skin Blisters From ‘Margarita Burn’ Frederick National Laboratory for Cancer Research: A Unique Resource for the...
